Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2019–2024

BactiVax · anti-Bacterial Innovative Vaccine Training Network.

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2019-10-01 → 2024-03-31
Финансиране от ЕС
4 009 373 €
Участници
12
Схема
MSCA-ITN

Линиите свързват координатора с партньорите.

Накратко на български

Ваксини срещу бактерии, които са устойчиви на антибиотици, като тези, причиняващи болнични инфекции или туберкулоза, са в центъра на разработката. Това е важно, за да се предотвратят тежки инфекции и да се ограничи разпространението им.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

anti-Bacterial Innovative Vaccine Training Network.

BactiVax was created to address the major health issue caused by the emergence of antimicrobial-resistant (AMR) bacteria, with a focus on those causing chronic, life-threatening respiratory and systemic infections. The research undertaken by the consortium targets a series of ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter sp.), which are the main cause of hospital-acquired infections globally and are highly resistant to almost all currently used antimicrobials. It also targets Mycobacterium tuberculosis (Mtb), which remains one of the biggest killers among infectious diseases worldwide. The premise of BactiVax is that vaccination against these pathogens will prevent infections and reduce their spread significantly. A central BactiVax focus is to design vaccines effectively, the project has four key objectives, illustrated through work packages (WP): 1. To identify novel, protective vaccine antigens against target pathogens (WP1). 2. To optimise the host response to the vaccines (WP2). 3. To optimise vaccine delivery (WP3). 4. To lead on vaccine advocacy (WP4). First and foremost, BactiVax is a research training programme that aims to provide first-class training in vaccinology to the next generation of vaccine researchers and equip them with a broad range of skills for thriving careers within academia or industry. For this, the consortium recruited 15 excellent Early Stage Researchers (ESRs), whose training is complete and includes a blend of research training, industrial secondments and courses to instil essential non-transferrable skills such as creativity, entrepreneurship, communication and management competencies (WP5).

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

BactiVax (anti-Bacterial Innovative Vaccine Training Network) is a European training network (ETN) that will provide high-level training in vaccinology to a new generation of 15 high-achieving, early-stage researchers (ESRs). This innovative ETN uniquely blends cutting-edge research training, non-academic placements and transferable skills. It will develop strong entrepreneurial and creative mindsets. BactiVax will train ESRs in a broad range of transferable skills enabling them to thrive in careers in vaccine research within academia and/or industry through discovery, development, and delivery of innovative therapeutic and prophylactic vaccines. The World Health Organisation has identified antimicrobial resistance (AMR) as one of the three greatest threats to mankind. There is a urgent need to train innovative ESRs in the development of new vaccines against AMR infections. BactiVax will tackle the societal challenge caused by the emergence of AMR pathogens and have significant impact on pathogens causing chronic, life-threatening respiratory and/or systemic infections. BactiVax training will cover critical areas of vaccinology from early antigen discovery to optimisation of host response and delivery of vaccine antigens. It will also encompass the increasing problem of vaccine hesitancy in its public engagement. The specific research objectives are to: 1) Identify novel, protective vaccine antigens against target pathogens; 2) Optimise the host response to vaccines; 3) Optimise vaccine delivery; 4) Lead on vaccine advocacy. BactiVax includes 2 SME beneficiaries, a multinational vaccine company and 4 SMEs as partners all of whom are involved in training, entrepreneurship, commercial vaccine development and vaccine antigen processing. All ESRs will have secondments in non-academic environment to enhance their exposure to the commercial. Overall, BactiVax will provide ESRs with rich experience and advanced multidisciplinary skills in the cutting edge area of vaccines

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз